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Summary
Background: Colorectal cancer remains a leading cause of mortality and morbidity.
The UK Bowel Cancer Screening Programme (BCSP) has demonstrated that detec-
tion of colorectal cancer at an earlier stage and identification of advanced pre‐malig-
nant adenomas reduces mortality and morbidity.
Aim: To assess the utility of volatile organic compounds as a biomarker for colorec-
tal neoplasia.
Methods: Faeces were collected from symptomatic patients and people participat-
ing in the UK BCSP, prior to colonoscopy. Headspace extraction followed by gas
chromatography mass spectrometry was performed on faeces to identify volatile
organic compounds. Logistic regression modelling and 10‐fold cross‐validation were
used to test potential biomarkers.
Results: One hundred and thirty‐seven participants were included (mean age 64 years
[range 22‐85], 54% were male): 60 had no neoplasia, 56 had adenomatous polyp(s)
and 21 had adenocarcinoma. Propan‐2‐ol was significantly more abundant in the can-
cer samples (P < 0.0001, q = 0.004) with an area under ROC (AUROC) curve of 0.76.
When combined with 3‐methylbutanoic acid the AUROC curve was 0.82, sensitivity
87.9% (95% CI 0.87‐0.99) and specificity 84.6% (95% CI 0.65‐1.0). Logistic regression
analysis using the presence/absence of specific volatile organic compounds, identified
a three volatile organic compound panel (propan‐2‐ol, hexan‐2‐one and ethyl 3‐
methyl‐ butanoate) to have an AUROC of 0.73, with a person six times more likely to
have cancer if all three volatile organic compounds were present (P < 0.0001).
Conclusions: Volatile organic compound analysis may have a superior diagnostic
ability for the identification of colorectal adenocarcinoma, when compared to other
faecal biomarkers, including those currently employed in UK.
Clinical trial details: National Research Ethics Service Committee South West ‐ Cen-
tral Bristol (REC reference 14/SW/1162) with R&D approval from University of
Liverpool and Broadgreen University Hospital Trust (UoL 001098).
The Handling Editor for this article was Professor Peter Gibson, and it was accepted for
publication after full peer‐review.
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1 | INTRODUCTION
Colorectal cancer is a leading cause of mortality and morbidity
worldwide, with an estimated European incidence of 43.5 per
100 000 in 2012 and mortality of 19.5 per 100 000.1 The lifetime
risk, for UK residents, is 1 in 15 for men or 1 in 19 for women.2
Across Europe, colorectal cancer is the second most common cause
of cancer‐related mortality.1 Colorectal cancer carries a significant
financial burden for the National Health Service, with a mean annual
cost of £12 000 and £8800 for each patient diagnosed with rectal
and nonrectal colon cancer respectively.3 Data from the UK Bowel
Cancer Screening Programme have clearly demonstrated that detec-
tion of colorectal cancer at an earlier stage and identification of
advanced pre‐malignant adenomas can reduce future cancer‐associ-
ated mortality and morbidity.4,5
The UK Bowel Cancer Screening Programme uses a faeces‐based
screening tool to select patients to take forward to colonoscopy, in
line with European guidance.6 Currently, in England, the guaiac‐
based faecal occult blood testing (gFOBt) is employed. This test
relies on bleeding from neoplastic lesions and can be used to identify
people with >10 mL rectal blood loss daily. gFOBt is however, prone
to false positive results after ingestion of certain foods.7 The low
sensitivity of gFOBt has led to criticism of its use for population‐
based screening.8 The gFOBt is likely to be replaced by faecal
immunochemical testing (FIT). FIT detects twice as many advanced
cancers as guaiac testing 9 and can provide both qualitative and
quantitative results. A recent observational study, from Italy, demon-
strated a reduction in colorectal cancer‐related mortality in regions
where screening with FIT was adopted compared with regions
where screening had not yet been implemented.10,11 Burch et al4
reported a meta‐analysis of 59 studies of FOBT: sensitivities for the
detection of all neoplasms ranged from 6.2% to 83.3% for gFOBTs
and 5.4% to 62.6% for FITs, depending on the preferred speci-
ficity.12 A review by NICE concluded that FIT has a specificity
ranging from 43% to 86%.13 However, FIT has limitations: the Dutch
colorectal cancer screening programme reported 77% sensitivity with
FIT based on 18 716 samples (specificity was not reported) and 23%
of the patients developed interval cancers.14
Several studies have reported volatile organic compounds emit-
ted from different substrates as biomarkers for colorectal cancer.
One such study used selected ion flow tube mass spectrometry
(SIFT‐MS) to detect volatile organic compounds in faeces.15 Another
analysed urine, from patients with colorectal cancer, employing Field
Asymmetric Ion Mobility Spectrometer (FAIMS).16 The third used
breath analysed by thermal‐desorber gas chromatography–mass
spectrometry (GCMS) in an attempt to diagnose colorectal can-
cer.17,18 These were mainly proof of concept or feasibility studies
that reported output patterns rather than identifying the individual
compounds. Therefore, understanding the biological plausibility for
patterns of volatile organic compounds can be difficult to interpret.
We undertook a prospective study of the volatile organic com-
pounds emitted from faecal samples obtained from patients at risk
of colorectal cancer.
2 | MATERIALS AND METHODS
2.1 | Participants
Most participants were recruited from colonoscopy waiting lists at
the Royal Liverpool University Hospital (n = 122). Participants were
referred by the Merseyside and Wirral Bowel Cancer Screening Pro-
gramme with positive FOBt or patients undergoing colonoscopy for
adenomatous polyp surveillance, planned polypectomy, the investiga-
tion of iron deficiency anaemia (IDA), change in bowel habit or
abnormal radiological imaging. All patients recruited via the Bowel
Cancer Screening Programme had a prior positive gFOBt. The FOBt
status of the non‐ Bowel Cancer Screening Programme patients was
unknown. No patients were assessed by FIT. Patient referrals and
Bowel Cancer Screening Programme referrals were vetted to assess
suitability and all consecutive patients were sent collection kits in
the post. A subset of the faecal samples was provided from a cohort
of symptomatic patients undergoing colonoscopy in Sheffield and
Plymouth, UK.
Research ethics committee approval for the study was obtained
from the National Research Ethics Service Committee South West ‐
Central Bristol (REC reference 14/SW/1162) with R&D approval from
University of Liverpool and Broadgreen University Hospital Trust
(UoL 001098) from where patients were recruited over a 12‐month
period. All patients were supplied with an information sheet and pro-
vided written consent. Specific permission was also granted by the
NHS Bowel Cancer Screening Programme Research Committee.
Samples collected from Sheffield (n = 11) and Plymouth (n = 6) were
acquired in line with existing ethical approval (North Sheffield
Research Ethics Committee (Ref: 06/Q2308/93 and 13/SW/0238,
respectively.
2.2 | Sample collection and storage
Samples were produced, at home, during the 48 hours preceding
their colonoscopy and before commencing the required bowel prepa-
ration. The stool was produced initially into a foil dish, then partici-
pants were asked to place at least three spoonfuls of faeces into a
glass vial (OdoReader, University of the West of England), before it
was sealed and stored in a cool place, either outside or in the fridge.
The initial volume of stool supplied by the patient was not specified
but could not exceed the volume of the provided 20 mL glass vial.
The sample was brought to the Endoscopy Department when the
patients attended for the colonoscopy. During the transportation
from the patient's home to the hospital the sample would have been
at ambient temperature. Patients who had received antibiotics in the
preceding 3‐6 months and vegetarians were excluded. Colonoscopy
results, including any histological findings, were recorded. Patients
were categorised as having no neoplasia, adenomatous polyp(s) or
cancer. Therefore, control patients were those with no neoplasia, but
they could have had other abnormalities including diverticulosis.
Patients with active colitis were excluded. The location, size and
number of polyps were recorded. Polyps were assigned to the
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adenoma group only after histological confirmation. Hyperplastic
polyps were classified as no neoplasia. Demographic details, smoking
status and antibiotic use were also recorded.
2.3 | Headspace volatile organic compound analysis
Four hundred and fifty milligram of unadulterated faeces was ali-
quoted into new 10 mL headspace vials and sealed with magnetic
caps (Supleco, Poole, UK).19 Both the sample intended for analysis
and the residual faeces were then stored at −20°C until GCMS anal-
ysis was performed.
Headspace volatile organic compounds analysis was performed
using a Combipal (CTC, Zwingen, Switzerland) and carboxen/poly-
dimethylsiloxane solid phase microextraction fibre (Sigma Aldrich,
Dorset, UK). The fibre was exposed to the headspace above the fae-
ces for 20 minutes. Volatile organic compounds were analysed by
GCMS (Perkin Elmer Clarus 500 quadrupole, Beaconsfield, UK): vola-
tile organic compounds were thermally desorbed from the fibre at
220°C in the injection port of the GCMS for 5 minutes. Injection
was made in splitless mode and a split of 50 mL/min was turned on
2 minutes into the run. Helium carrier gas of 99.996% purity (BOC,
Guildford, UK) was passed through a helium purification system,
Excelasorb™ (Supelco) at 1 mL/min. The GC column was a 60 metre
long Zebron ZB‐624 capillary column with an inner diameter of
0.25 mm. The column (Phenomenex, Macclesfield, UK) was lined
with a 1.4 μm film of 94% dimethyl polysiloxane and 6%
cyanopropylphenyl. The GCMS temperature program of the run was
as follows: initial oven temperature was held at 40°C for 2 minutes
then the temperature was ramped up at a rate of 5°C/min to 220°C,
with a 4 minute hold at this temperature to give a total run time of
42 minutes. The mass spectrometer was run in electron impact (EI)
ionisation mode, scanning the mass ion range 10‐300 at 0.05 scan/s.
A 4 minute solvent delay was used at the start of the run.19–21
2.4 | Data processing
The GCMS data were processed using a pipeline involving the Auto-
mated Mass Spectral Deconvolution and Identification System soft-
ware (AMDIS, Version 2.71, 2012), the NIST mass spectral library
(version 2.0, 2011) and the R (R core team, 2013) package Metab.22
AMDIS and NIST software were used to build a volatile organic
compound library containing 162 metabolites present in the stool
samples analysed in this study. A forward and reverse match of 800/
1000 and above was used for assigning tentative compound identifi-
cations. Using this volatile organic compound library, AMDIS was
then applied to deconvolute chromatograms and identifying metabo-
lites. The report generated by AMDIS was further processed by
Metab, in order to align metabolites and recalculate their relative
abundances based on the intensity of a specific ion mass fragment
per metabolite. In order to develop robust parsimonious statistical
models, those compounds found to be present in fewer than 20% of
the patients in both groups were removed.20,21 Compounds were
named using IUPAC nomenclature.
2.5 | Statistical analysis
Data analysis was performed in R, Stata and Metaboanalyst,23 utilis-
ing Student's t test, Mann‐Whitey tests, Fisher's exact test, ANOVA,
false discovery rate correction, Partial Least Squared Discriminant
Analysis (PLS‐DA), factor analysis and Receiver Operator Characteris-
tic (ROC) analysis. Logistic regression modelling, along with 10‐fold
cross‐validation was used to test potential biomarkers. When
Metaboanalyst was used the data were normalised by median and
log‐transformed. When Mann‐Whitney and factor analysis was used
the data were logged, normalised and the absence of a volatile
organic compound substituted by the value ‐3 to create an artificial
floor in keeping with the concept that the lack of an observable
volatile organic compound is analogous to the least amount measur-
able.
3 | RESULTS
One hundred and thirty‐seven patients were included in the study:
the average age was 64.3 years; 56% were male. The mean age was
lowest in those with no neoplasia and greatest in those with the
cancer, P = 0.02. None of the participants reported being smokers or
vegetarians. Self‐reported ethnicity was noted: all but one was
White British. 27.7% of study participants were recruited from the
Bowel Cancer Screening Programme.
One hundred and sixty‐two volatile organic compounds were
identified in whole sample set. The mean number of volatile organic
compounds identified in each group was similar: cancer (mean 54.3,
standard deviation [SD] 1.2), adenoma (mean 55.0, SD 11.6) or con-
trols (mean 54, SD 10.3). Biomarker identification focused on higher
risk neoplastic disease, namely established colorectal cancer and >4
individual polyps of any size.
Initially samples from patients in all three groups were compared
using ANOVA. Fourteen volatile organic compounds differed in
abundance: after adjusting for multiple comparisons, none were sig-
nificant, but several were of interest as they were found in later
comparisons, including 5‐methyl‐2‐propan‐2‐yl‐cyclohexan‐1‐ol, ethyl
3‐methylbutanoate and propan‐2‐ol (Table 1).
3.1 | Volatile organic compounds as a biomarker
for colonic adenocarcinoma: quantitative analysis
PLS‐DA comparing those with no neoplasia and those with colorec-
tal cancer showed a separation that suggested potential diagnostic
utility (Figure 1). Exploration of potential candidates for biomarker
analysis can be seen in Table 2. These comparisons did not include
samples from patients with adenomatous polyps: only those with
confirmed adenocarcinoma and no neoplasia were included for anal-
ysis.
Propan‐2‐ol and 5‐methyl‐2‐propan‐2‐yl‐cyclohexan‐1‐ol was fur-
ther considered in isolation, following assessment when combining
volatile organic compound as a ratio. The latter was formerly known
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as dl‐menthol: we will use that name to aid readability. Propan‐2‐ol
selected as it was the volatile organic compound most strongly asso-
ciated with cancer; dl‐menthol as it was the only volatile organic
compound to be negatively associated with cancer.
The abundance of propan‐2‐ol was compared in the three groups
using Kruskal Wallis test. The mean abundance in cancer was
88.7 × 106, in adenoma 23.7 × 106 and controls 51.5 × 106; the
differences were significant, P = 0.001 (Figure 2). The data were log‐
transformed and compared using ANOVA: the differences were sig-
nificant (P = 0.01), post hoc Dunnett testing showed the main differ-
ence was between samples from patients with cancer and controls
(P = 0.007): this implies that, while the mean for adenomas was
appeared less than that for controls, the adenoma data were widely
spread. It is noteworthy, of the other compounds associated with
cancer, three are esters of propan‐2‐ol with short chain acids.
The abundance of dl‐menthol was subjected to the same analy-
sis. The mean abundance in cancer was 0.7 × 106, in adenoma
15.1 × 106 and controls 8.3 × 106; the differences were significant,
P = 0.04. The data were log‐transformed and compared using
ANOVA: the differences were significant (P = 0.003), post hoc Dun-
nett testing showed patients with cancer had significantly less dl‐
menthol than adenoma and control groups.
Propan‐2‐ol showed the most promise as a single biomarker for
colorectal cancer: it achieved an area under the ROC (AUROC) curve
TABLE 1 Demographic and clinical features of participants
recruited in Liverpool, Sheffield and Plymouth
No‐neoplasia Adenoma Cancer
Number 60 56 21
Mean age, years (range) 61.9 (22‐85) 65.6 (41‐84) 72.7 (64‐78)
Gender
Male 25 36 7
Female 34 20 3
Smoker (yes) 0 0 0
Indication for colonoscopy
BCSP 13 22 3
IDA 16 6 5
Change in bowel
habit‐diarrhoea
11 4 1
Surveillance previous
neoplasia/FH
10 24 1
IBD assessment/
surveillance
9 0 0
GI bleeding 1 0 0
Unknown 0 0 11
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F IGURE 1 Partial least square discriminate analysis comparing
those with adenocarcinoma of the colon (red) and no colonic
neoplasia (green)
TABLE 2 Volatile organic compounds with abundance that differs
significantly between samples from patients with cancer and controls
VOC P value q value
Association
with CRC:
Propan‐2‐ola <0.0001 0.004 Positive
Hexan‐2‐one 0.01 0.77 Positive
Ethyl 3‐methylbutanoatea 0.03 0.77 Positive
Propan‐2‐yl butanoate 0.03 0.77 Positive
Propan‐2‐yl pentanoate 0.03 0.77 Positive
1,4‐xylene 0.03 0.77 Positive
Propan‐2‐yl propanoate 0.04 0.77 Positive
5‐methyl‐2‐propan‐
2‐yl‐cyclohexan‐1‐ola
0.05 0.77 Negative
Significance was determined by Student's t test applied to log‐trans-
formed data. The q value was reported after adjustment for multiple
comparisons.
aVolatile organic compounds identified in the ANOVA.
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F IGURE 2 Box plots to show the relative abundance of propan‐
2‐ol in faeces from all participants. All patients in each cohort are
included Normal (no neoplasia) n = 60, adenoma n = 56 and cancer
n = 21
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(Figure 3) to predict colorectal cancer of 0.76 with a sensitivity of
83% and specificity of 71%.
Calculating ratios of all possible metabolite pairs and then choos-
ing top ranked ratios, based on p values, allowed for further biomar-
ker assessment.
A hold‐out technique was applied to the 81 samples (21 cancer
and 60 controls) in order to validate the combination of 3‐methyl
butanoic acid/propan‐2‐ol as a biomarker for colorectal cancer: 50%
of each cohort were held back. The combination of 3‐methylbu-
tanoic acid and propan‐2‐ol gave the best result: data from patients
with cancer and with no neoplasia were modelled using logistic
regression and 10‐fold cross‐validation, based upon the abundance
of 3‐methylbutanoic acid and propan‐2‐ol (Table 3): AUROC is 0.86,
sensitivity 87.9% (95% CI 0.87‐0.99) and specificity 84.6% (95% CI
0.65‐1.0).
3.2 | Assessing for patterns of volatile organic
compounds as biomarkers for colonic
adenocarcinoma‐ factor analysis using qualitative data
Principal component analysis and a non‐orthogonal rotation feature
analysis was applied to qualitative (presence/absence) data for vola-
tile organic compounds using all volatile organic compounds that
was present in at least 30% of the group for any of the three diag-
nostic groups. Using all the data, the solution could not be extracted
due to convergence issues (because many of the volatile organic
compounds were highly correlated with each other) until the number
of extracted factors had been reduced from 19 to 17.
By looking at the factors, rather than the individual volatile
organic compounds, to fit a regression model to predict cancer a
number of different orthogonal rotations were used to produce a set
of potential predictors. This process highlighted the combination of
propan‐2‐ol, hexan‐2‐one and ethyl 3‐methylbutanoate as a key pre-
dictor. Used as continuous variables directly extracted from the data
set (prior to logging and normalisation) the simple summation of the
quantities of these three peaks produces AUROCs of 0.768 and
0.750. Using a simple summation of the presence and absence of all
three volatile organic compounds as a biomarker panel predicted
cancer patients distinctly from all other patients with a P = 0.001
and an AUROC of 0.73 and predicted cancer versus normal with a
P = 0.006 and an AUROC 0.702, suggesting very little information is
lost by using just presence and absence of these three compounds.
It is noteworthy that these three volatile organic compounds were
also found by the univariate analysis, before correction for multiple
comparisons.
Pure reference solutions of propan‐2‐ol, hexan‐2‐one and ethyl
3‐methylbutanoate confirmed the identification within the stool sam-
ples was correct.
3.3 | Volatile organic compounds as a biomarker
for colonic adenomas: quantitative analysis
Several volatile organic compounds were associated with samples
from patients with >4 polyps (Figure 4). None of the associations
remained after adjustment for multiple comparisons.
4 | DISCUSSION
Correctly identifying patients to undergo colonoscopy as part of
population‐based screening is vital in order to maximise pathology
capture and to minimise unnecessary examinations. There is a clear
link to improved outcomes from colorectal cancer through the iden-
tification of earlier stage colorectal cancer and pre‐malignant
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F IGURE 3 Receiver operating characteristic curve for propan‐2‐ol
when comparing those with adenocarcinoma of the colon and no
colonic neoplasia
TABLE 3 Area under the receiver operating characteristic results
for the volatile organic compounds emitted when using a
comparison of ratios for those with adenocarcinoma of the colon
and no colonic neoplasia
VOC ratio combination AUROC 95% CI
Optimal
sensitivity
%
Optimal
specificity
%
3‐methylbutanoic acid/
propan‐2‐ol
0.82 0.71‐0.92 81 76
dl‐Menthol/propan‐2‐ol 0.82 0.7‐0.91 85 71
Nonan‐2‐one/
propan‐2‐ol
0.81 0.7‐0.91 88 57
2‐methylpropanoic
acid/propan‐2‐ol
0.81 0.7‐0.91 80 76
Decane/propan‐2‐ol 0.81 0.68‐0.9 81 71
Pentyl acetate/
propan‐2‐ol
0.8 0.69‐0.89 83 71
Phenylacetaldehyde/
propan‐2‐ol
0.79 0.65‐0.91 86 76
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adenomatous colonic polyps.5 This study has demonstrated the util-
ity of volatile organic compounds emitted from faeces to act as a
biomarker for colonic neoplasia, in particular adenocarcinoma.
We have reported two volatile organic compound‐based models
for the identification of samples from patients with adenomas and
colorectal cancer. In the quantitative approach, the models were
dominated by the presence of propan‐2‐ol either as an alcohol or as
an ester with short chain fatty acids. The qualitative model, which
simply used presence or absence of compounds, also included pro-
pan‐2‐ol.
Propan‐2‐ol is a secondary alcohol that may be derived from ace-
tone: a pathway associated with Clostridria.24 The role of propan‐2‐
ol in the pathogenesis of colorectal cancer had not been proposed
before: the occurrence in this study may be a bystander phe-
nomenon linked to dysbiosis; further work is needed. Ethyl 3‐
methylbutanote probably arises from a condensation reaction
between ethanol and 3‐methylbutanoic acid. Ethanol is produced by
several metabolic pathways. 3‐Methylbutanoic acid is derived from
3‐methylbutanal, by aldehyde dehydrogenase: the aldehyde is
derived from leucine.
Using a variety of methods and substrates, other studies have
suggested a utility of volatile organic compound analysis for the
diagnosis of GI disease,20,25–27 including colorectal cancer. One such
study, from 2015, used selected ion flow tube mass spectrometry to
analysis volatile organic compounds emitted from faeces of FOBt
positive patients. Comparing patients with no neoplasia and high
grade neoplasia, ions probably arising from hydrogen sulphide,
dimethyl sulphide and dimethyl disulphide were significantly higher
in samples from high risk compared to low risk subjects. The authors
reported overall specificity of 78% and 72% sensitivity (Table 4).15
Two separate studies, from 2014 and 2013, reported the analysis of
volatile organic compounds found in urine and breath, respectively.
The study examining urine used Field Asymmetric Ion Mobility Spec-
trometer (FAIMS): 133 patients were included; 83 colorectal cancer
patients and 50 healthy controls. Sensitivity and specificity for col-
orectal cancer detection with FAIMS were 88% and 60% respec-
tively.16 A third technology, in the form of thermal‐desorber gas
chromatography–mass spectrometry, was used to assess volatile
organic compounds in the study examining breath. Assessing the
pattern of 15 compounds showed a sensitivity of 86%, a specificity
of 83% and AUROC of 0.85.17 More recently, using the same tech-
nique, this group described the ability of exhaled volatile organic
compounds to discriminate between colorectal cancer patients
before and after curative surgery.18 A further study from 2014
reported the utility of a pattern recognition–based detection tech-
nique, using volatile organic compounds found in faeces. This study
did not attempt to identify the individual compounds but focused on
differing patterns. It attempted to identify established colorectal can-
cer and pre‐malignant adenomatous lesions. Faecal volatile organic
compound profiles of patients with colorectal cancer differed signifi-
cantly from controls (AUROC, 0.92; sensitivity, 0.85; and specificity,
0.87). Patients with advanced adenomas could also be distinguished
from controls (AUROC, 0.79; sensitivity, 0.62; and specificity, 0.86).
Population‐based screening or a point of care test is the most
likely clinical application of such volatile organic compound analysis.
Despite their relatively low patient acceptance rates, faecal based
techniques are currently the most commonly employed ie, FOBt,
either gFOBt or FIT. The gFOBT currently used in the UK Bowel
Cancer Screening Programme has a sensitivity of 36% and a speci-
ficity of 94% for the detection of colorectal cancer.28,29 To date,
there are no controlled trials that demonstrate that FIT is superior to
gFOBT or to no screening in terms of reducing colorectal cancer‐re-
lated mortality in average risk persons. However, a recent observa-
tional study from Italy demonstrated a reduction in colorectal
cancer‐related mortality in regions where screening with FIT was
adopted compared with regions where screening had not yet been
implemented 10,11 The superiority of FIT over gFOBts is now widely
recognised and the European Quality Assurance Guideline on
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TABLE 4 Propan‐2‐ol, hexan‐2‐one and ethyl 3‐methylbutanoate
in stool from patients with colonic adenocarcinoma, adenomatous
colonic polyps and no neoplasia
Adenoma Cancer Normal
Mean number of
these three VOCs
1.16 2.0 1.33
Proportion with
none of these
three VOCs
23.2% (13/56) 0% (0/21) 20.0% (12/60)
With just 1 42.8% (24/56) 23.8% (5/21) 36/7% (22/60)
With just 2 28.6% (16/56) 52.4% (11/21) 33.3% (20/60)
With all three 5.4% (3/56) 23.8% (5/21) 10.0% (6/60)
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Colorectal Cancer Screening published in 2011 recommends FIT in
preference to gFOBT.30,31 Studies have reported FIT to have overall
sensitivity for colorectal cancer was 0.79 (95% CI: 0.69‐0.86) and
the overall specificity was 0.94 (95% CI: 0.92‐0.95).32 Various coun-
tries have adopted FIT into their colorectal cancer screening pro-
grammes and the Bowel Cancer Screening Programme plans to
replace gFOBt with FIT.33 Comparing the result of our study it
would appear that volatile organic compounds have a greater diag-
nostic ability than either FOBt for the identification of colorectal
cancer. In the future patient acceptability may be improved by the
use of ingestible capsules.34,35
Further work is necessary to ascertain the source of the volatile
organic compounds that were found in association with colorectal
cancer and adenomas. It is likely that they are bacterial metabolites.
The driver‐passenger model of colorectal cancer development sug-
gests that Fusobacterium nucleatum is the key to ongoing tumouroge-
nesis, with butanoic acid playing a key role in supporting the tumour
microenvironment.36 The presence of F. nucleatum in colorectal can-
cer tissue has also been noted in more advanced colorectal cancer,
particularly those with lymph node metastasis, again supporting the
positive correlation.37,38 F. nucleatum (data not shown, paper in
preparation) has been shown to produce propan‐2‐ol (data not
shown, paper in preparation) and may be a source of propan‐2‐ol in
colorectal cancer samples.
Moreover, we demonstrated a significant decrease in dl‐menthol
in those with colorectal cancer. This commonly originates from den-
tal hygiene products. F. nucleatum is found in the oral cavity and
thus poor dental hygiene is linked to increase in F. nucleatum and
potentially increased the risk of colorectal cancer. Thus, the absence
of dl‐menthol might indicate the presence of poor hygiene and the
carriage of F. nucleatum.
The heterogenous nature of the study cohort is a limitation as it
limits the generalisability of the results to an asymptomatic screening
population. As with techniques employed in population‐based
screening there is reliance on the patients to appropriately collect
and handle the samples, our methods has this limitation, therefore
potentially introducing error here. All attempts were made in the
patient selection, sampling equipment, storage, transportation and
laboratory analysis to minimise volatile organic compound contami-
nation and variability. We wanted to simplify the procedures as
much as possible in this pilot. Patients collected samples in their
own homes and brought them to the Endoscopy Department just as
they do for calprotectin assessment. Any influence of handling sam-
ples in this way would have acting upon cases and controls and is
unlikely to have materially affected the statistical separation of the
data.
5 | CONCLUSIONS
This pilot study has found compounds that are positively and nega-
tively associated with the presence of colorectal neoplasia. Volatile
organic compounds emitted from faeces can be utilised as a
biomarker for colorectal cancer. Prospective studies are required to
determine whether volatile organic compounds are better than FIT
testing or whether they should be used together.
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